Camlipixant (BLU-5937) is currently undergoing clinical testing. All investigational products must be tested in clinical trials before they can be approved by the U.S. Food and Drug Administration and similar regulatory authorities worldwide.
Expanded Access Policy
At this time, BELLUS’ investigational therapy is not available on an expanded access or right-to-try basis for new patients. In the event BELLUS decides to consider expanded access or right-to-try use, the Company will evaluate and respond to each request that it receives on a case-by-case basis. For more information on our investigational therapy and ongoing clinical trials, please visit bellushealth.com/pipeline/blu-5937 or clinicaltrials.gov.
GSK has completed its acquisition of BELLUS Health.